Trial
NCT00679029
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
University of Nebraska
Collaborators
National Cancer Institute (NCI)
Condition
HER2-negative Breast Cancer
Intervention
doxorubicin hydrochloride
Why stopped
drug toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-12-11